Daily Newsletter

30 August 2023

Daily Newsletter

30 August 2023

Clearblue introduces new menopause stage indicator in US

The Menopause Stage – Clearblue me app can be used to securely store results from the indicator.

RanjithKumar Dharma August 30 2023

Procter & Gamble’s brand Clearblue has entered the menopause market with the launch of the new Menopause Stage Indicator in the US.

The Clearblue Menopause Stage Indicator is claimed to be the first and only product to integrate the urine follicle-stimulating hormone (FSH) measurements of a woman with her age and cycle history to determine her probable stage of menopause.

The free-to-download Menopause Stage – Clearblue me app can be used to securely store results from the indicator.

The app combines the results of five urine FSH tests, along with age and cycle history, to determine the likely menopause stage.

For an informed conversation about menopause and potential treatment options, consumers can generate and print their personalised report to bring to their clinicians.

Furthermore, women can use the app for tracking symptoms and cycles besides accessing educational content and articles to manage symptoms and prepare for the doctor’s visit.

Clearbluebrand director Leah Wood said: “The topic of menopause has 10x more searches than fertility, yet only makes up 25% of the conversation size.

“The silence around it is palpable and it’s our hope that if women have more information about where they are in their menopause journey, they’ll feel more empowered to turn up the volume, talk about it, and embrace this new stage in life.”

The Clearblue portfolio includes several products, including advanced digital ovulation tests, fertility monitors, digital pregnancy tests, rapid detection pregnancy tests and others.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close